Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?

BACKGROUND: It is unknown whether the outcomes of second-line pemetrexed-carboplatin chemotherapy administered after progression on gefitinib are dependent on type of EGFR mutation present at baseline. METHOD: Adult non-small-cell lung cancer patients, with exon 19 deletion or exon 21 L858R mutation...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Chemother Res Pract
Main Authors: Joshi, Amit, Noronha, Vanita, Patil, Vijay M., Chougule, Anuradha, Bhattacharjee, Atanu, Kumar, Rajiv, Goud, Supriya, More, Sucheta, Ramaswamy, Anant, Karpe, Ashay, Pande, Nikhil, Chandrasekharan, Arun, Goel, Alok, Talreja, Vikas, Mahajan, Abhishek, Janu, Amit, Purandare, Nilendu, Prabhash, Kumar
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi 2017
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5672602/
https://ncbi.nlm.nih.gov/pubmed/29201462
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/8196434
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados